Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated CLL

PURPOSE: Although rituximab-based chemoimmunotherapy (CIT) has substantially improved clinical outcomes in chronic lymphocytic leukemia (CLL), only 40-50% of patients achieve a complete remission (CR). There remains interest in identifying new approaches to improve the effectiveness of CIT. Ofatumum...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Shanafelt, Tait, Lanasa, Mark C., Call, Timothy G, Beaven, Anne W., Leis, Jose F., LaPlant, Betsy, Bowen, Deborah, Conte, Michael, Jelinek, Diane F., Hanson, Curtis A., Kay, Neil E., Zent, Clive S.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894149/
https://ncbi.nlm.nih.gov/pubmed/23922059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28292
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items